The global Direct-acting Antiviral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Direct-acting Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct-acting Antiviral Drugs.

Report Scope

The Direct-acting Antiviral Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Direct-acting Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Direct-acting Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Direct-acting Antiviral Drugs Market Report

Report Metric	Details
Report Name	Direct-acting Antiviral Drugs Market
CAGR	5%
Segment by Type	NS3/4A Protease Inhibitors Nucleoside and Nucleotide NS5B Polymerase Inhibitors NS5A Inhibitors Non-Nucleoside NS5B Polymerase Inhibitors
Segment by Application	Hospitals Clinics Ambulatory Surgical Centers Pharmacies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie Inc., GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Roche, Bristol-Myers Squibb Company, Gilead Sciences, Janssen (Johnson & Johnson), Vertex Pharmaceuticals, Natco Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Direct-acting Antiviral Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Direct-acting Antiviral Drugs Market report?

Ans: The main players in the Direct-acting Antiviral Drugs Market are AbbVie Inc., GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Roche, Bristol-Myers Squibb Company, Gilead Sciences, Janssen (Johnson & Johnson), Vertex Pharmaceuticals, Natco Pharma

What are the Application segmentation covered in the Direct-acting Antiviral Drugs Market report?

Ans: The Applications covered in the Direct-acting Antiviral Drugs Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies, Others

What are the Type segmentation covered in the Direct-acting Antiviral Drugs Market report?

Ans: The Types covered in the Direct-acting Antiviral Drugs Market report are NS3/4A Protease Inhibitors, Nucleoside and Nucleotide NS5B Polymerase Inhibitors, NS5A Inhibitors, Non-Nucleoside NS5B Polymerase Inhibitors

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 NS3/4A Protease Inhibitors

1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors

1.2.4 NS5A Inhibitors

1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors

1.3 Market by Application

1.3.1 Global Direct-acting Antiviral Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Pharmacies

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Direct-acting Antiviral Drugs Market Perspective (2019-2030)

2.2 Direct-acting Antiviral Drugs Growth Trends by Region

2.2.1 Global Direct-acting Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2019-2024)

2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2025-2030)

2.3 Direct-acting Antiviral Drugs Market Dynamics

2.3.1 Direct-acting Antiviral Drugs Industry Trends

2.3.2 Direct-acting Antiviral Drugs Market Drivers

2.3.3 Direct-acting Antiviral Drugs Market Challenges

2.3.4 Direct-acting Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue

3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2019-2024)

3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue

3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio

3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2023

3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served

3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service

3.7 Date of Enter into Direct-acting Antiviral Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Direct-acting Antiviral Drugs Breakdown Data by Type

4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2019-2024)

4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2025-2030)

5 Direct-acting Antiviral Drugs Breakdown Data by Application

5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2019-2024)

5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Direct-acting Antiviral Drugs Market Size (2019-2030)

6.2 North America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Direct-acting Antiviral Drugs Market Size by Country (2019-2024)

6.4 North America Direct-acting Antiviral Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Direct-acting Antiviral Drugs Market Size (2019-2030)

7.2 Europe Direct-acting Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Direct-acting Antiviral Drugs Market Size by Country (2019-2024)

7.4 Europe Direct-acting Antiviral Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2019-2030)

8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Direct-acting Antiviral Drugs Market Size (2019-2030)

9.2 Latin America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Direct-acting Antiviral Drugs Market Size by Country (2019-2024)

9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2019-2030)

10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie Inc.

11.1.1 AbbVie Inc. Company Detail

11.1.2 AbbVie Inc. Business Overview

11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction

11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.1.5 AbbVie Inc. Recent Development

11.2 GSK

11.2.1 GSK Company Detail

11.2.2 GSK Business Overview

11.2.3 GSK Direct-acting Antiviral Drugs Introduction

11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.2.5 GSK Recent Development

11.3 Boehringer Ingelheim

11.3.1 Boehringer Ingelheim Company Detail

11.3.2 Boehringer Ingelheim Business Overview

11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction

11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.3.5 Boehringer Ingelheim Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck Direct-acting Antiviral Drugs Introduction

11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.4.5 Merck Recent Development

11.5 Novartis

11.5.1 Novartis Company Detail

11.5.2 Novartis Business Overview

11.5.3 Novartis Direct-acting Antiviral Drugs Introduction

11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.5.5 Novartis Recent Development

11.6 Beximco Pharmaceuticals

11.6.1 Beximco Pharmaceuticals Company Detail

11.6.2 Beximco Pharmaceuticals Business Overview

11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction

11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.6.5 Beximco Pharmaceuticals Recent Development

11.7 Roche

11.7.1 Roche Company Detail

11.7.2 Roche Business Overview

11.7.3 Roche Direct-acting Antiviral Drugs Introduction

11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.7.5 Roche Recent Development

11.8 Bristol-Myers Squibb Company

11.8.1 Bristol-Myers Squibb Company Company Detail

11.8.2 Bristol-Myers Squibb Company Business Overview

11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction

11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.8.5 Bristol-Myers Squibb Company Recent Development

11.9 Gilead Sciences

11.9.1 Gilead Sciences Company Detail

11.9.2 Gilead Sciences Business Overview

11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction

11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.9.5 Gilead Sciences Recent Development

11.10 Janssen (Johnson & Johnson)

11.10.1 Janssen (Johnson & Johnson) Company Detail

11.10.2 Janssen (Johnson & Johnson) Business Overview

11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction

11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.10.5 Janssen (Johnson & Johnson) Recent Development

11.11 Vertex Pharmaceuticals

11.11.1 Vertex Pharmaceuticals Company Detail

11.11.2 Vertex Pharmaceuticals Business Overview

11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction

11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.11.5 Vertex Pharmaceuticals Recent Development

11.12 Natco Pharma

11.12.1 Natco Pharma Company Detail

11.12.2 Natco Pharma Business Overview

11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction

11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2019-2024)

11.12.5 Natco Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Beximco Pharmaceuticals

Roche

Bristol Myers Squibb Company

Gilead Sciences

Janssen (Johnson& Johnson)

Vertex Pharmaceuticals

Natco Pharma

List of Tables

Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of NS3/4A Protease Inhibitors

Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors

Table 4. Key Players of NS5A Inhibitors

Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors

Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Direct-acting Antiviral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Direct-acting Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Direct-acting Antiviral Drugs Market Share by Region (2019-2024)

Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Direct-acting Antiviral Drugs Market Share by Region (2025-2030)

Table 12. Direct-acting Antiviral Drugs Market Trends

Table 13. Direct-acting Antiviral Drugs Market Drivers

Table 14. Direct-acting Antiviral Drugs Market Challenges

Table 15. Direct-acting Antiviral Drugs Market Restraints

Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2019-2024)

Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2023)

Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Direct-acting Antiviral Drugs Product Solution and Service

Table 23. Date of Enter into Direct-acting Antiviral Drugs Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global Direct-acting Antiviral Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2019-2024)

Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2025-2030)

Table 33. North America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Direct-acting Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Direct-acting Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Direct-acting Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Direct-acting Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Direct-acting Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Direct-acting Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Direct-acting Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 48. AbbVie Inc. Company Detail

Table 49. AbbVie Inc. Business Overview

Table 50. AbbVie Inc. Direct-acting Antiviral Drugs Product

Table 51. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 52. AbbVie Inc. Recent Development

Table 53. GSK Company Detail

Table 54. GSK Business Overview

Table 55. GSK Direct-acting Antiviral Drugs Product

Table 56. GSK Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 57. GSK Recent Development

Table 58. Boehringer Ingelheim Company Detail

Table 59. Boehringer Ingelheim Business Overview

Table 60. Boehringer Ingelheim Direct-acting Antiviral Drugs Product

Table 61. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 62. Boehringer Ingelheim Recent Development

Table 63. Merck Company Detail

Table 64. Merck Business Overview

Table 65. Merck Direct-acting Antiviral Drugs Product

Table 66. Merck Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 67. Merck Recent Development

Table 68. Novartis Company Detail

Table 69. Novartis Business Overview

Table 70. Novartis Direct-acting Antiviral Drugs Product

Table 71. Novartis Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 72. Novartis Recent Development

Table 73. Beximco Pharmaceuticals Company Detail

Table 74. Beximco Pharmaceuticals Business Overview

Table 75. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product

Table 76. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 77. Beximco Pharmaceuticals Recent Development

Table 78. Roche Company Detail

Table 79. Roche Business Overview

Table 80. Roche Direct-acting Antiviral Drugs Product

Table 81. Roche Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 82. Roche Recent Development

Table 83. Bristol-Myers Squibb Company Company Detail

Table 84. Bristol-Myers Squibb Company Business Overview

Table 85. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product

Table 86. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 87. Bristol-Myers Squibb Company Recent Development

Table 88. Gilead Sciences Company Detail

Table 89. Gilead Sciences Business Overview

Table 90. Gilead Sciences Direct-acting Antiviral Drugs Product

Table 91. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 92. Gilead Sciences Recent Development

Table 93. Janssen (Johnson & Johnson) Company Detail

Table 94. Janssen (Johnson & Johnson) Business Overview

Table 95. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product

Table 96. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 97. Janssen (Johnson & Johnson) Recent Development

Table 98. Vertex Pharmaceuticals Company Detail

Table 99. Vertex Pharmaceuticals Business Overview

Table 100. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product

Table 101. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 102. Vertex Pharmaceuticals Recent Development

Table 103. Natco Pharma Company Detail

Table 104. Natco Pharma Business Overview

Table 105. Natco Pharma Direct-acting Antiviral Drugs Product

Table 106. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 107. Natco Pharma Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Direct-acting Antiviral Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Direct-acting Antiviral Drugs Market Share by Type: 2023 VS 2030

Figure 3. NS3/4A Protease Inhibitors Features

Figure 4. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features

Figure 5. NS5A Inhibitors Features

Figure 6. Non-Nucleoside NS5B Polymerase Inhibitors Features

Figure 7. Global Direct-acting Antiviral Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Direct-acting Antiviral Drugs Market Share by Application: 2023 VS 2030

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Ambulatory Surgical Centers Case Studies

Figure 12. Pharmacies Case Studies

Figure 13. Others Case Studies

Figure 14. Direct-acting Antiviral Drugs Report Years Considered

Figure 15. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Direct-acting Antiviral Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Direct-acting Antiviral Drugs Market Share by Region: 2023 VS 2030

Figure 18. Global Direct-acting Antiviral Drugs Market Share by Players in 2023

Figure 19. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2023

Figure 21. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Direct-acting Antiviral Drugs Market Share by Country (2019-2030)

Figure 23. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Direct-acting Antiviral Drugs Market Share by Country (2019-2030)

Figure 27. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2019-2030)

Figure 35. China Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Direct-acting Antiviral Drugs Market Share by Country (2019-2030)

Figure 43. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2019-2030)

Figure 47. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 50. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 51. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 52. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 54. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 55. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 56. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 57. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 58. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 59. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 60. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Antiviral Drugs Market

Influenza Diagnostics Market

Influenza Antiviral Drugs Market

Antiviral Therapy Market

HIV Therapeutics Market

Protease Inhibitors Market

Hepatitis B Therapeutics Market

Anti Viral Coatings Market

Sterile and Antiviral Packaging Market

Specific Antiviral Drugs for COVID 19 Market

Novel Antiviral Drugs Market

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions